Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zinc & prostate cancer

This article was originally published in The Tan Sheet

Executive Summary

Chronic zinc oversupply "may play a role in prostate carcinogenesis," according to data compiled by Michael Leitzmann, MD, National Institutes of Health, et al., appearing in July 2 Journal of the National Cancer Institute. Researchers found that "compared with nonusers, men who consumed more than 100 mg per day of supplemental zinc had a relative risk of advanced prostate cancer of 2.29, and men who took supplemental zinc for ten or more years" had a relative risk of 2.37. Leitzmann et al. studied data collected from 46,974 men in the Health Professionals Follow-Up Study between 1986 and 2000. Residual confounding by supplemental calcium intake or by an unmeasured correlate of zinc supplement use could explain these findings, researchers suggest, although they recommend further investigation...

You may also be interested in...

Zinc and prostate cancer

A study finds "no statistically significant association" between zinc supplementation and prostate cancer risk, according to a letter in the Journal of the National Cancer Institute by the study authors. Ellen Chang, Karolinska Institute, Stockholm, et al., conducted a population-based case-control study among 1,499 prostate cancer patients and 1,130 control subjects, finding no increase in prostate cancer risk arising from supplemental zinc use categorized by frequency, duration or cumulative exposure. The results contradict a 2003 JNCI study that reported a greater risk of prostate cancer among users of supplemental zinc (1"The Tan Sheet" July 14, 2003, In Brief)...

Generics Firms Deterred From Continuous Manufacturing

Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.

Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts

Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts